AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01649453 — intervention group
Intervention type: DEVICE
Intervention: Pathwork® Tissue of Origin Test
Study NCT02721394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training
Description: Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
Study NCT00918008 — intervention group
Intervention type: GENETIC
Intervention: Blood draw
Description: The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
Study NCT03661476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oculo-Motor Exercises (OME)
Description: Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes.
Study NCT03635580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative control
Description: Untreated-control group
Study NCT03866395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5 mg twice a day
Study NCT00998218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
Study NCT00998218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
Study NCT02781740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Positive Air Pressure Device
Study NCT02781740 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continous Positive Air Pressure Device
Study NCT01122264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally for 24 weeks.
Study NCT01122264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Administered orally for 24 weeks.
Study NCT04622800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise, proprioceptive neuromuscular fasilition (PNF) techniques
Description: PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
Study NCT03751254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellaris Elite
Description: The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length > 25.0 mm) during cataract surgery
Study NCT04140227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: 100% Perfluorohexyloctane
Study NCT05171452 — intervention group
Intervention type: BIOLOGICAL
Intervention: Urine and stoll samples
Description: Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
Study NCT00412373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for 6 weeks
Study NCT00412373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: (3-12mg/day in 3 mg/day increments for 6 weeks)
Study NCT02826720 — intervention group
Intervention type: OTHER
Intervention: No intervention was applied
Description: No intervention was applied
Study NCT01889381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow cell-based therapy & 1-drug immunosuppression.
Description: This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
Study NCT03523923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care
Description: Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~* Care Management Weekly monitoring of response to treatment using standardized measures.~* Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~* Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals.
Study NCT00708253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double-balloon procedure (DBE)
Description: Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
Study NCT00708253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-balloon procedure (SBE)
Description: Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
Study NCT00354185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00354185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study NCT00354185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00354185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02270853 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sleep apnea screening with ApneaLinkTM
Description: ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
Study NCT02047344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
Study NCT01106417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: Single Dose NeoFuse Surgical Implantation
Study NCT01106417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MasterGraft Granules
Description: Single Dose MaterGraft Granules Surgical Implantation
Study NCT04098055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-Made Foot Orthoses
Description: The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
Study NCT04098055 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
Study NCT04232969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide extended release 2mg (Bydureon)
Description: Subcutaneous Injection
Study NCT04232969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide extended release 2mg (Bydureon)
Description: Subcutaneous Injection
Study NCT01252667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic PBSCT
Study NCT01252667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT01252667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT01252667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01252667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01252667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic PBSCT
Study NCT01252667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies
Study NCT01252667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00833417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg
Description: Vismodegib 150 mg was provided in hard gelatin capsules.
Study NCT02811523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin by In Vivo Lung Perfusion
Study NCT03330002 — intervention group
Intervention type: DEVICE
Intervention: CE-marked MANTA vascular closure device (VCD)
Description: Compile real word data on MANTA VCD.
Study NCT02639858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PM
Description: Docetaxel PM 75mg/m2 IV infusion
Study NCT01445548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT03951168 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine Management
Description: Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
Study NCT03951168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Management
Description: Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
Study NCT00853216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride tablet 30 mg
Description: Oxycodone hydrochloride tablet 30 mg, single dose fasting
Study NCT00853216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxicodone™ tablet 30 mg
Description: Roxicodone™ tablet 30 mg, single dose fasting
Study NCT03561688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot orthotics
Description: Insoles for shoes
Study NCT03561688 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard insole
Description: Sham foot orthotic
Study NCT03702244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cCTA with selective FFRct
Description: PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
Study NCT04092023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nursing education
Description: Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
Study NCT02314403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: A selective T-cell (lymphocyte) costimulation blocker
Study NCT02314403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: A T-Cell Depleting Agent
Study NCT03044600 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
Study NCT03044600 — intervention group
Intervention type: OTHER
Intervention: HRPT2 Mutation Evaluation
Description: Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
Study NCT00713310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 400 mg
Description: High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM
Study NCT00713310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 400 mg
Description: Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM
Study NCT03081156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate / Formoterol
Description: Exercise Tolerance
Study NCT03081156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycopyrrolate / Formoterol
Description: Exercise Tolerance
Study NCT05453734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercises
Description: Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
Study NCT00228982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril
Study NCT00228982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT04717206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyomtric training to male badmninton players
Description: Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills.
Study NCT02314403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: B-Cell Depleting Agent
Study NCT06418620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Tablet-Route of administration:Oral
Study NCT00940277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Counseling
Description: Group counseling
Study NCT00200265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet
Study NCT00200265 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: diet
Description: diet
Study NCT00947648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Raw Fruits & Vegetables
Description: Diet containing fresh fruits and vegetables in addition to cooked food.
Study NCT00947648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cooked Foods
Description: Diet containing only cooked foods.
Study NCT01628926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study NCT02314403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Study NCT01628926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Description: Ropinirole oral administration TID up to 15.0 mg/day
Study NCT01628926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SPM962-placebo patch and Ropinirole-placebo tab
Study NCT03624647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power toothbrush
Description: Experimental power toothbrush
Study NCT03624647 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual toothbrush
Description: Marketed manual toothbrush
Study NCT03135249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab
Description: Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
Study NCT01459978 — intervention group
Intervention type: OTHER
Intervention: CUmulative SUM (CUSUM) Chart
Description: Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose
Study NCT02300493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: Asked to weigh themselves
Study NCT02300493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Asked to weigh themselves
Study NCT04096534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normotonic partial nephrectomy
Description: partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg
Study NCT04096534 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic partial nephrectomy
Description: partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
Study NCT00312455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-eicosapentaenoic acid (EPA)
Description: 450 mg 5x/day
Study NCT00312455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-docosapentaenoic acid (DPA)
Description: 100mg 5x/day
Study NCT00312455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules/day
Study NCT02314403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thymic Irradiation
Study NCT02314403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Bone Marrow/Kidney Transplantation
Study NCT02605525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SM101
Description: Human soluble recombinant Fcγ Receptor IIB
Study NCT02605525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20